The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of perioperative capecitabine plus oxaliplatin (CapeOx) therapy for advanced gastric cancer with multiple lymph node metastases (OGSG 1701).
 
Shunji Endo
Honoraria - Johnson & Johnson; Ono Pharmaceutical
Research Funding - Mitsubishi Tanabe Pharma (Inst); Yakult Honsha (Inst)
 
Yutaka Kimura
Honoraria - EA Pharma
Research Funding - DAIICHI SANKYO COMPANY, LIMITED
 
Naotoshi Sugimoto
Research Funding - Astellas Pharma (Inst); BeiGene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Solasia Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Ryohei Kawabata
No Relationships to Disclose
 
Atsushi Takeno
No Relationships to Disclose
 
Jin Matsuyama
No Relationships to Disclose
 
Motohiro Imano
No Relationships to Disclose
 
Hisato Kawakami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst)
 
Shigeyuki Tamura
No Relationships to Disclose
 
Masato Nakamura
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck
 
Hiroki Takeshita
No Relationships to Disclose
 
Shogen Boku
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Taiho Pharmaceutical
Research Funding - Daiichi Sankyo Co. Ltd. (Inst)
 
Yukinori Kurokawa
Honoraria - Daiichi Sankyo; Johnson & Johnson; Kaken Pharmaceutical; Lilly; MC Medical; Medtronic; Nippon Kayaku; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Toshio Shimokawa
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiihi-Sankyo; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)